SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Issuer
PURSUANT to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934
For the Month of October, 2006
Commission File Number 0-30860
Axcan Pharma Inc.
(Exact Name of Registrant)
597, boul, Laurier, Mont-Saint-Hilaire (Quèbec), Canada J3H 6C4
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F | Form 40-F |
| X |
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also hereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes | No |
| X |
This Form 6-K consists of: Axcan Pharma Inc.’s September 29, 2006 press release entitled “Axcan Receives FDA Approval Letter for PyleraTM (formerly known as Helizide), an Innovative 3-in-1 Capsule Triple Therapy for the Eradication of Helicobacter Pylori.”
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
AXCAN PHARMA INC.
Date: October 2, 2006 | By: | /s/ Steve Gannon |
| Name: | Steve Gannon |
| Title: | Senior Vice President and Chief Financial Officer |
